Abstract
Introduction Angiogenesis in physiology and pathology
Angiogenesis or neovascularization -the growth of new capillaries from pre-existing microvasculature [1] -sustains tissue growth and repair in normal adult physiology: during wound healing, ovarian and endometrial cycling, as well as muscle adaptations to exercise training [2, 3] . Angiogenesis can occur through distinct pathways: elevated microvascular shear stress triggers splitting angiogenesis, the intraluminal splitting of a microvessel longitudinally into two vessels; while tissue hypoxia stimulates sprouting angiogenesis, the abluminal budding of a new capillary sprout laterally from an existing microvessel [3, 4] . Related to splitting angiogenesis is intussusceptive angiogenesis caused by the formation of transvascular tissue pillars dividing the existing microvessel [5] . [6] .
Tight regulation of the dynamic equilibrium between pro-angiogenic (angiogenic) and anti-angiogenic (angiostatic) processes is critical to health, as an imbalance in either direction contributes to a myriad of pathological conditions. Diseases characterized by excessive and abnormally coordinated angiogenesis include cancer, retinopathy, choroidal neovascularization, arthritis, atherosclerosis, psoriasis and endometriosis, whereas heart, brain and peripheral ischemia, as well as diabetes, hypertension, pre-eclampsia and nephropathy are characterized by insufficient angiogenesis

Angiogenesis in current medicine
The wide range of 'angiogenesis-dependent diseases' offers the promise of angiogenesis as a therapeutic target. In clinical trials designed to manipulate the 'angiogenic balance' in vivo as a therapeutic strategy [2, 7, 8] 
, anti-angiogenic therapy seeks to downregulate angiogenesis stimulators and/or up-regulate angiogenesis inhibitors; while pro-angiogenic therapy aims to up-regulate angiogenesis stimulators and/or down-regulate angiogenesis inhibitors. At the molecular level, common targets of these therapeutic angiogenesis inhibitors and stimulators are the ligands and receptors of the vascular endothelial growth factor (VEGF) system, in which the ligand VEGF transduces pro-angiogenic signals through receptor tyrosine kinases such as VEGFR2 (VEGF receptor-2), while the soluble receptor sVEGFR1 is inhibitory to angiogenic signalling, partially through VEGF sequestration.
In the category of anti-angiogenic therapy, a prime research focus has been on the development of angiogenesis inhibitors as anti-cancer drugs, including the FDA-approved bevacizumab (a humanized monoclonal antibody against VEGF), sorafenib and sunitinib (receptor tyrosine kinase inhibitors) [9] ; many others still in clinical trials, including endostatin (a broad-spectrum endothelial cell inhibitor) [10, 11] ; and recently, the gene/protein delivery of sVEGFR1 in pre-clinical studies [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . Recent studies have demonstrated synergistic benefits of combining specific anti-angiogenic therapy with conventional chemotherapy (the use of cytotoxic agents in targeting proliferating tumour cells) [9, 22] . [23, 24] . These randomized, controlled clinical trials have not been able to reproduce the efficacy consistently observed in pre-clinical animal studies [23, 24] . One proposed reason is that patients with these vascular diseases may also suffer from ligand insensitivity due to impaired receptor signalling or increased expression of antagonists (e.g. sVEGFR1), rather than simply a deficiency in angiogenic growth factor expression [23, 25] . [23, 26, 27] .
In the category of pro-angiogenic therapy, also known as therapeutic angiogenesis, almost a dozen clinical trials have been conducted for the gene and protein delivery of VEGF to treat coronary artery disease (CAD) and peripheral arterial disease (PAD), which are atherosclerotic vascular diseases that result in muscle ischemia
Another proposed reason is that the pharmacokinetics of VEGF administration are not optimal for localizing pro-angiogenic responses within ischemic tissue, and that systemic elevation of angiogenic growth factors in blood may contribute to: (i) side effects such as transient tissue oedema (VEGF strongly induces vascular permeability) and (ii) the counter-effect of further promoting angiogenesis at the vasa vasorum feeding the growth of primary atherosclerotic plaques
VEGF ligand and receptor system: where does sVEGFR1 fit? Ligands: the human VEGF family
Human VEGF is a family of related proteins: VEGF-A, VEGF-B and
PlGF (placental growth factor) primarily involved in the growth of blood vessels [28, 29] ; and VEGF-C and VEGF-D primarily involved in lymphangiogenesis (growth of lymphatic vessels) [30] . VEGF is secreted in cysteine-linked dimeric form [28] , primarily as anti-parallel homodimers (VEGF/VEGF) but possibly as heterodimers (e.g. PlGF/VEGF) [31] .
In most adult tissues, VEGF-A (also commonly referred to as simply VEGF) is secreted primarily from mesenchymal, stromal and epithelial sources (e.g. myocytes in muscles; platelets in blood; tumour cells and stromal cells in tumours) to act on endothelial cells in a paracrine fashion [9, 32, 33] . The biological roles traditionally attributed to VEGF have thus been mostly vascular: promoting the survival, migration, and proliferation of endothelial cells and increasing vascular permeability of vessels [28, 33] . Both the sprouting and splitting modes of angiogenesis are dependent on VEGF-A [3, 4] . However, there is a growing list of non-vascular roles for VEGF (e.g. recruitment of inflammatory cells and endothelial precursor cells [33] ; neuroprotection in central nervous system and retina [34] ), as well as evidence for autocrine and intracrine production and function of VEGF (e.g. in endothelial, tumour and haematopoietic stem cells [9, 35] [36, 37] . The VEGF-A exons conferring isoform-specific affinities with receptors and co-receptors are illustrated in Fig. 1 [23, 24] .
PlGF is also an important ligand for VEGFR1 and sVEGFR1, but not for VEGFR2 [28] (Fig. 1) . The pathological disorder of preeclampsia sheds light on the critical interplay between PlGF and sVEGFR1. There is increasing evidence that hypoxia-induced placental production of sVEGFR1 plays a causal role in the pathogenesis of pre-eclampsia, a pregnancy disorder in which placental hypoxia and maternal endothelial dysfunction lead to multi-organ disease including hypertension and proteinuria [38] [39] [40] [41] . In preeclampsia, increased circulating sVEGFR1 has been correlated with reduced free PlGF and reduced free VEGF in the blood compared to normal pregnancies [41] [42] [43] [44] [45] .
Membrane-bound signalling receptors: VEGFRs
Full-length VEGF receptors-1, -2 and -3 (VEGFR1, VEGFR2, VEGFR3) are membrane-tethered receptor tyrosine kinases that are activated through homo/hetero-dimerization and ligandinduced trans-phosphorylation of intracellular tyrosine residues [29] . VEGFR3, as the receptor for VEGF-C and VEGF-D, largely mediates lymphangiogenic signalling [46] and will not be discussed here. VEGFR1 and VEGFR2 are expressed primarily on endothelial cells and they predominantly partake in the regulation of blood vessel angiogenesis (regulation of capillary sprouting and splitting), blood vessel maintenance, endothelial cell migration, endothelial cell proliferation, blood vessel permeability and dilation of blood vessels [28, 33] [34] .
VEGFR2 (also known as KDR in human beings and Flk-1 in mice) is considered the predominant effector of pro-angiogenic signalling in sprouting angiogenesis and endothelial cell survival [9] . VEGFR2 is specific to VEGF-A and does not bind PlGF [29] (Fig. 1) .
On the other hand, VEGFR1 (also known as FLT-1 in human beings and Flt-1 in mice) binds both VEGF-A and PlGF [29] (Fig. 1) , and can mediate either anti-or pro-angiogenic signalling depending on the activating ligand type [46] . VEGF-A binding to VEGFR1 is generally considered anti-angiogenic -possibly due to sequestration of VEGF-A which lowers its availability for VEGFR2 activation, although direct intracellular signal transduction has not been ruled out [31, [46] [47] [48] [51, 52] . A comparatively less prevalent diffusible source is the heparin-II binding domains of soluble fibronectins [53] . There are also HSPGs tethered on cell surfaces that facilitate surface VEGF-VEGFR binding and modulate the internalization rates of resultant complexes [46] .
The cell-surface glycoproteins neuropilin-1 (NRP1) and neuropilin-2 (NRP2) were discovered originally as neuronal axon guidance receptors, but later found to be functionally significant in vascular formation as well [28, 54] . NRP1 directly binds VEGF165, PlGF-2 and possibly to a weaker degree, VEGF121 [55] ; NRP2 additionally binds VEGF145 and VEGF-C, suggesting a functional bias for lymphangiogenesis [28, 46, 54] .
NRPs are typically considered non-signalling receptors, but they serve as co-receptors for the VEGF family via complex formation with VEGFRs [46] . The presence of NRP1 exerts an overall pro-angiogenic effect on VEGF-signalling through two synergistic mechanisms [56] . Firstly, NRP1 can couple with VEGFR1 directly, with the resultant unligated complex NRP1-VEGFR1 permissive to subsequent binding by VEGF121 but not VEGF165 [56] . In other words, NRP1 makes VEGFR1 less available for VEGF165 activation, thereby decreasing inhibitory or modulatory VEGFR1 signalling through the VEGF165 isoform [56] . Secondly, NRP1 cannot couple VEGFR2 directly, but can still form a VEGFR2-VEGF165-NRP1 complex through non-overlapping VEGFR2-binding and NRP1-binding sites on the VEGF165 'bridge' [56] . In this manner, NRP1 augments VEGF165 activation of VEGFR2 by both stabilizing VEGF165-VEGFR2 complexes and presenting NRP1-bound VEGF165 to VEGFR2, thus increasing pro-angiogenic VEGFR2 signalling through the VEGF165 isoform [56, 57] . An illustration and detailed discussion can be found in Mac Gabhann et al. [56] .
Soluble receptors
Soluble VEGF receptor-1 (sVEGFR1) was initially cloned in 1993 [58] and is a truncated ~110 kDa splice variant of the 180 kDa membrane-spanning VEGFR1 [28, 45, 59] . The natural occurrence of sVEGFR1 -derived predominantly from alternative splicing [58] , but possibly also from proteolytic cleavage of full-length VEGFR1 [16] -has been well documented, first in the pathophysiology of pre-eclampsia, and more recently also in numerous other physiological conditions [40, 41] [45, 60] . As discussed in detail below, there is growing interest in biomedical research to explore sVEGFR1 as a disease marker [42, [61] [62] [63] and a therapeutic vector for angiogenesis inhibition [12, 18, 64] .
There is emerging evidence for soluble forms of other receptors as well. Soluble VEGFR2 is present in significant quantities in healthy human plasma (7-8 ng/ml) [65] and is up-regulated in acute myeloid leukaemia [66] . Soluble NRP1, a VEGF165-specific antagonist, has been documented in the kidney in human beings [67, 68] . However, this mini review will focus on sVEGFR1.
Molecular biology of sVEGFR1
The molecular weight of sVEGFR1 appears to be both glycosylation-and species-dependent. The size of sVEGFR1 has been documented as 60 kDa in mice [69] [58, 59] , 220-230 kDa [58, 59] and 600-700 kDa [70] , respectively, which suggests ligand-induced di/multi-merization, but the relative proportions of these various forms in vivo have yet to be quantified.
While sVEGFR1 has traditionally been considered a single protein, emerging evidence point to a family of at least four alternatively spliced soluble VEGFR1 proteins [71] . The mRNA transcripts of all known sVEGFR1 variants are common through to exon 13 [46, 58] (Fig. 2) . Kendall et al. [58] and traditionally referred to as 'sFlt-1', ends with an extension of exon 13; (ii) sFlt1_v2, identified by Thomas et al. as 'sFlt1-e15a' in 2007 [72] and Sela et al. as 'sFlt1-14' in 2008 [73] , includes exon 14 and terminates with exon 15a sequences [73] ; (iii) sFlt1_v3, identified in 2009 by Heydarian et al. [71] , includes exon 14 and terminates with exon 15b and (iv) sFlt1_v4, also identified by Heydarian et al. in 2009 [71] , includes exon 14 and terminates with an extension of exon 14. A detailed illustration of the structural differences between the 3Ј terminal exons of sVEGFR1 splice variants can be found in Heydarian et al. [71] Evidently, the splice variants of sVEGFR1 are subject to species-specific and cell-type-specific differential regulation at both transcriptional and translational levels, although the molecular details of which are still unclear [71, 73] . Hypoxia has been observed to up-regulate sVEGFR1 expression via HIF1-␣, a process that likely contributes to the pathogenesis of pre-eclampsia [74] .
The four known splice variants differ in their unique C-terminus as follows: (i) sFlt1_v1, originally discovered in 1993 by
Furthermore, an in vitro study documented in microvascular endothelial cells a ␥-secretase-dependent intramembrane proteolysis of membrane-bound VEGFR1 and the intracellular release of an 80 kDa C-terminal fragment [16] . This finding prompted speculations of extracellular shedding of the remnant ~100 kDa N-terminal fragment, which may contribute to the interstitial/plasma population of sVEGFR1 as a proteolytically cleaved counterpart to its alternatively spliced forms. More recently, ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR1 was further documented in human leukaemia cancer cells [75] . Hereafter in this review, 'sVEGFR1' will refer to the entire family of alternatively spliced and cleaved variants of sVEGFR1. [76, 77] ; the third and fourth domains are responsible for heparin-binding [77] , suggesting possible sequestration at interstitial matrix sites (e.g. on heparan sulphate proteoglycans); NRP1-binding is mediated mostly through the third, but also the fourth, domain [77] and the fourth domain is responsible for ligand-induced receptor dimerization [76, 78] , which presumably can facilitate both sVEGFR1-sVEGFR1 homodimerization and sVEGFR1-VEGFR heterodimerization.
Theoretically, the molecular interactions of sVEGFR1 with VEGF family ligands are expected to be similar to those of VEGFR1 due to preservation of the first six Ig-like domains: the first three domains, especially the second and third, are involved in the binding of competing ligand family members, including VEGF-A, VEGF-B and PlGF
Physiological and pathophysiological roles of sVEGFR1
Endogenous sources of sVEGFR1 in human beings include vascular endothelial cells [40] , vascular smooth muscle cells [73] , activated peripheral blood mononuclear monocytes [40] , placental trophoblasts [40] , corneal epithelial cells [79] and proximal tubular cells of the renal epithelia [80] . As alluded to, there is evidence for cell type-specific production of sVEGFR1 splice variants: human vascular smooth muscle cells were found to express sFlt1-14 while human endothelial cells expressed the traditional sFlt-1 [73] . This wide assortment of cell types capable of sVEGFR1 expression would suggest its active involvement in multiple physiological and pathological conditions. Several biological functions of sVEGFR1 have been deduced from its capacity to neutralize VEGF: (1) anti-angiogenesis, by dampening angiogenic VEGF-VEGFR2 signalling [12, 46] ; (2) antioedema, by interfering with VEGF-mediated vascular permeability through VEGFR1 or VEGFR2 [46, 81] and (3) [87] . In vitro evidence supports a critical role for sVEGFR1 in vessel branching [88] , but it remains unclear whether this is due to sVEGFR1-mediated attenuation of interstitial gradients or sVEGFR1 heterodimerization with surface VEGFRs. [89, 90] [76, 78] 
Computational simulation of these biomolecular interactions provides an important means to decipher the relative contributions of each mechanism to sVEGFR1's anti-angiogenic effects
. Experimentally, whether dominant-negative heterodimerization plays a significant role in vivo may be determined by quantifying the differential anti-angiogenic effects of sVEGFR1 versus ECD1-3 (the first three extracellular Ig-like domains of VEGFR1), which may not be able to dimerize with surface VEGFR, as the fourth Ig-like domain appears to play a role in receptor dimerization
sVEGFR1 as a clinical marker for disease
Since 2000, at least 20 studies [27, 42-44, 61-63, 66, 80, 91-101] [41, 44, 45] . Quantitative metrics have shown predictive value for sVEGFR1 in differentiating pre-eclampsia among suspected pregnancies [42, 43] [61, 66, 91, 93] 
have quantified sVEGFR1 levels in a diverse range of diseases associated with pathological changes of VEGF or PlGF levels, as summarized in Tables 3 to 5. Most measurements in Tables 3-5 were of circulating (plasma/serum) sVEGFR1, but a few measurements were from urine and tissue (brain) extracts as well. Researchers are increasingly finding clinical utility for sVEGFR1 as a diagnostic (disease identification) and/or prognostic (disease progression) marker in diverse medical conditions, either independently or in combination with VEGF or PlGF (Table 3). As noted, it is well established that increased circulating sVEGFR1 and reduced free PlGF and free VEGF in the blood are correlated with the pregnancy disorder pre-eclampsia (a disease of endothelial dysfunction and impaired angiogenesis) compared to normal pregnancies
. In liver cirrhosis (an inflammatory disease of pro-angiogenic status), increases in plasma VEGF
Fig. 3 How sVEGFR1 inhibits angiogenic signalling at the cell surface: two postulated mechanisms. The full set of possible ligand-receptor complexes in the absence of sVEGFR1 is shown in the middle row; those marked with 'ϩ' and '-' are thought to transduce pro-and anti-angiogenic signals, respectively. The presence of sVEGFR1 allows new combinations of complexes (top and bottom rows) that do not signal (marked by '0'); these non-signalling species exert anti-angiogenic effects by competing for ligands with pro-angiogenic species. Specifically, in mechanism 1 (top row), sVEGFR1 homodimers (or monomers, not shown) directly compete with surface VEGFRs for ligands (e.g. VEGF and PlGF), effectively lowering free ligand concentrations available to bind unoccupied surface VEGFRs. In mechanism 2 (bottom row), sVEGFR1 monomers dimerize with surface VEGFR monomers to form dominant-negative heterodimer complexes, effectively lowering the density of functional surface VEGFRs available to bind free ligands. These two mechanisms are not mutually exclusive and both are likely to occur in vivo, although their relative propensities are not known. 'P1' and 'P2' ϭ placental growth factors-1 and -2; 'V121' and 'V165' ϭ vascular endothelial growth factor-A (VEGF) isoforms 121 and 165; '1', '2', 'N' ϭ surface receptors VEGFR1, VEGFR2, neuropilin-1; 's1' ϭ soluble VEGFR1.
and sVEGFR1 were associated with a degree of hepatic insufficiency [62] . In suspected sepsis (systemic inflammation induced by infection), plasma sVEGFR1 and VEGF have shown potential for predicting illness severity or septic shock [63] , where the changes in sVEGFR1 are thought to reflect a compensatory protective response to the VEGF-dependent inflammation [63, 102, 103] (Fig. 5A) (Fig. 5B) (Fig. 5C) . Thus, the simultaneous measurement of circulating VEGF and sVEGFR1 -a major VEGF neutralizing agent -in attempt to quantify the actual bioavailability of circulating VEGF, still does not uniformly predict the angiogenic status across the diseases examined here. (4) 
Firstly, plasma VEGF is elevated in almost all diseases/conditions
, including the neoplastic diseases (acute myeloid leukaemia), diseases of abnormal ocular neovascularizations (retinopathy, glaucoma), inflammatory diseases (cirrhosis, sepsis) and diseases of cardiac and peripheral ischemia (CAD, PAD). Thus plasma VEGF alone cannot serve as a differential marker for angiogenic status. Secondly, there is not a consistent trend in plasma sVEGFR1 level changes within the diseases of supposedly similar angiogenic status
Fig. 4 How sVEGFR1 attenuates extracellular VEGF gradients and hinders capillary sprout migration: postulated mechanisms. The interstitial VEGF gradients that endothelial vessel sprouts sense and respond to in migration may consist of: (1) matrix-bound VEGF, (2 a-b) free diffusible VEGF, (3) MMP-cleaved active fragment VEGF113 and
Systems biology perspective: unifying interpretation of plasma angiogenic markers
This section examines potential flaws and pitfalls in relying on just two markers in isolation -the plasma VEGF and sVEGFR1 levelsto encapsulate the angiogenic status of angiogenesis-dependent diseases.
We also propose that a more integrative systems biology perspective [104, 105] can benefit the interpretation of these markers to aid prediction of the angiogenic status across a diversity of physiological and pathophysiological conditions.
1.Baseline heterogeneity in clinical measurements of healthy VEGF and sVEGFR1 levels in plasma
The quantitative variability in published measurements of circulating VEGF is well documented and can span up to three orders of magnitude due to inter-study differences in assay protocols [106, 107] . Similarly, inter-study heterogeneity in measurements of circulating sVEGFR1 was reported in a meta-analysis of 10 studies examining normal pregnancies versus pre-eclampsia [44] . Having normalized the sample sources in Fig. 5 to consider only plasma measurements, healthy VEGF levels still varied over an order of magnitude from 14.3 pg/ml to 580 pg/ml, while healthy sVEGFR1 levels varied by three orders of magnitude from 22.5 pg/ml to 28 ng/ml. This striking data variability may be attributable to interstudy methodological differences, such as in the definition of inclusion/exclusion criteria of healthy cohorts, or in the sampling, preparation and analysis of blood protein concentrations. In particular, the healthy measurements of sVEGFR1 can be divided into two extreme ranges (Fig. 5) , with one set well below 2 ng/ml and the other above 15 ng/ml; it is uncertain whether the systematically higher values reported in the latter dataset [27, [95] [96] [97] [98] 101] could be accounted for by the in-house modified ELISA protocols commonly used in those studies (Table 3) . Methodological disparities aside, natural variation of the physiological baseline could account for the wide intra-study ranges observed among individuals within control groups [27, 44] 
2.Effect of sVEGFR1 on VEGF bioavailability: VEGF-sVEGFR1 complexes
The rationale behind using VEGF:sVEGFR1 ratios as indicators of angiogenic status [61, 93] is based on an assumption that sVEGFR1 is the predominant regulator of circulating VEGF bioavailability, other than the intrinsic VEGF production rates. This assumption has yet to be validated, in light of mounting evidence of other potential blood carriers of VEGF: soluble VEGFR2 [65, 66] , soluble NRP1 [67, 68] , plasma fibronectin [53, [108] [109] [110] [111] and platelets [112] . Furthermore, sVEGFR1 itself has additional ligand partners in addition to VEGF-A, as it also binds VEGF-B and placental growth factor (PlGF) [87, 113] . 
4.Pathogenic phenomenon versus compensatory response
